Meyka Pro banner
Ligand Pharmaceuticals Incorporated

Stay Updated with the Latest Ligand Pharmaceuticals Incorporated LGND News in Real Time

Find LGND news now at Meyka AI. Stay informed with the latest Ligand Pharmaceuticals Incorporated stocks updates, including price news, market analysis, and expert insights.

LGNDNASDAQ
HealthcareBiotechnology
$286.29
$1.10(0.38%)
U.S. Market opens in 60h 41m
Gaja Alternative IPO GMP Today: How Gaja Capital Is Challenging the AIF Model
📅 1 day ago

Gaja Alternative IPO GMP Today: How Gaja Capital Is Challenging the AIF Model

Gaja Alternative IPO’s Grey Market Premium stood at ₹21 as of Thursday, August 20, 2026, 9:45 AM IST. That implies a listing price near ₹181, a 13% premium over the ₹160 upper band. The ₹550 crore issue from Gaja Capital’s asset management arm closes for subscription on August 21. Overall subscription remained modest at 0.30…

Read more 12
Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update
📅 1 day ago

Moderna Soars 177% on Melanoma Vaccine Win; August 20 Update

Moderna jumped 177% to $174.38 after Phase 3 melanoma vaccine trial success with Merck. The mRNA therapy reduced recurrence risk and represents the first approved late-stage cancer vaccine.

Read more 12
AstraZeneca (LON: AZN) Halts Phase 3 Lung Cancer Trial After Volrustomig Fails to Show Survival Benefit
📅 4 days ago

AstraZeneca (LON: AZN) Halts Phase 3 Lung Cancer Trial After Volrustomig Fails to Show Survival Benefit

AstraZeneca has halted a late-stage trial of its lung cancer drug Volrustomig, marking a fresh pipeline setback. The FTSE 100 company said the drug, combined with chemotherapy, was unlikely to improve survival rates. An Independent Data Monitoring Committee recommended stopping the Phase 3 trial after a planned review.  This marks AstraZeneca’s second major trial halt…

Read more 12
2,500 Organizations Hit by LiteLLM Supply Chain Attack in March
📅 8 days ago

2,500 Organizations Hit by LiteLLM Supply Chain Attack in March

LiteLLM supply chain attack in March 2026 exposed 2,500+ organizations and 434,000 CI/CD pipelines. Malicious code ran for 40 minutes, stealing AWS, GCP, and Azure credentials from major tech companies.

Read more 12
Technocraft Ventures IPO Subscription Hits 6.98x on Day 3 as NII Demand Leads
📅 10 days ago

Technocraft Ventures IPO Subscription Hits 6.98x on Day 3 as NII Demand Leads

Technocraft Ventures IPO closed its subscription window Tuesday, August 11, 2026, at 6.98 times overall. Non-institutional investors drove the strongest demand, pushing this EPC infrastructure issue well past full subscription. The ₹251.88 crore mainboard IPO priced shares between ₹200 and ₹212. Strong grey market activity suggests investors expect a solid listing debut this week. Technocraft…

Read more 12
MV Electrosystems Debuts at 22% Premium on NSE, Lists at ₹520 Against IPO Price of ₹425
📅 15 days ago

MV Electrosystems Debuts at 22% Premium on NSE, Lists at ₹520 Against IPO Price of ₹425

MV Electrosystems shares listed on the NSE on Thursday, August 6, 2026, at ₹520 per share. That marks a 22% premium over the IPO price of ₹425. The railway equipment maker’s mainboard debut drew strong investor interest throughout its three-day subscription window. Trading began at 10 a.m. on both NSE and BSE simultaneously. MV Electrosystems…

Read more 12
Juniper Green Energy IPO Opens Today at ₹214–225 Price Band; GMP at ₹17 Signals 8% Listing Premium
📅 23 days ago

Juniper Green Energy IPO Opens Today at ₹214–225 Price Band; GMP at ₹17 Signals 8% Listing Premium

Juniper Green Energy IPO opened for subscription on Thursday, July 30, 2026. The ₹1,800 crore issue is priced between ₹214 and ₹225 per share. Grey Market Premium stands at ₹17, suggesting a listing gain of roughly 7% to 8%. The renewable energy IPP will remain open for bidding until August 3, 2026. Juniper Green Energy…

Read more 12
FDA Issues Class II Recall for Subpotent Levothyroxine Tablets on July 28
📅 24 days ago

FDA Issues Class II Recall for Subpotent Levothyroxine Tablets on July 28

Major Pharmaceuticals recalls levothyroxine sodium tablets nationwide due to subpotency. The FDA classified it as a Class II recall on July 17. Affected patients should consult their doctor and return medication to the pharmacy.

Read more 12
Should You Apply for Xtranet Technologies IPO? Day 3 GMP and Subscription Analysis
📅 26 days ago

Should You Apply for Xtranet Technologies IPO? Day 3 GMP and Subscription Analysis

Xtranet Technologies IPO closes today, July 27, 2026, its third and final subscription day. The issue has been subscribed 2.88 times as of Day 3 morning. That’s a sharp jump from 1.07 times on Day 1 and 1.49 times on Day 2. Grey market premium, however, has fallen to just ₹6 per share today. That…

Read more 12

LGND News FAQ